Cite
HARVARD Citation
Modest, D. et al. (n.d.). PD-020Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study. Annals of oncology. p. . [Online].